Market News AIOpen the app

DRMA stock news · Dermata Therapeutics, Inc.

Stories about Dermata Therapeutics, Inc. (DRMA) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for DRMA

Follow Dermata Therapeutics, Inc. (DRMA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for DRMA
Free on the App Store and Google Play, or on the web.
  1. Oct 29, 2026, 5:31 PM ET · Market

    Dermata Therapeutics says the first person has joined its acne treatment trial.

    Neutral

    DRMA says its acne-treatment study has started and expects a launch in the first half of 2027. No results are reported, and the filing gives conflicting dates.

  2. Oct 15, 2026, 1:49 PM ET · Market

    Dermata Therapeutics stock is going up on Thursday after good news from a study.

    Good for DRMA

    Dermata reported that users saw improvements with its newly launched skin treatment. The small, open-label study gives the product early support, but does not show whether sales will grow.

  3. Oct 15, 2026, 1:20 PM ET · Market

    On Thursday, 12 health care stocks saw big price changes, with Regencell Bioscience jumping up 30.4%.

    Neutral

    Dermata Therapeutics shares rose 24% in Thursday's session, but the article gives no company update. This trading report does not change the outlook for Dermata Therapeutics' business.

  4. Aug 12, 2026, 5:23 AM ET · Market

    Dermata Therapeutics shares climb 27% in pre-market trading: What’s driving the movement?

    Neutral

    Dermata Therapeutics' shares jumped nearly 28% in pre-market trading after the company reported its Q2 earnings, which, despite missing analyst estimates, were overshadowed by the announcement of a new skincare product launch. This strategic pivot towards commercialization is expected to generate revenue soon, enhancing investor confidence.